Cidofovir injection (trade name: Vistide) 1996 was first listed in the United States, and then listed in Britain, France, Italy and other countries. Gilead is responsible for the sales of Vistide in the US market, and the overseas market is under the responsibility of its partner Pharmacia Corporation (now Pfizer).
The gel dosage form of cidofovir for external use was developed by Gilead company. After completing phase I and phase II clinical trials, its application for marketing (refractory HSV infection in AIDS patients) was rejected by FDA in 2004 because of insufficient clinical data (the specific reason is unknown). Gilead has stopped developing the gel preparation of cidofovir for external use (Direct Communication, Gilead, June 29th, 2004). There is no report on the subsequent development of this company and other companies.
In addition, there are some reports of antiviral research on animal models using cidofovir eye drops.